Collection of Biological Samples From Patients With Rare Neurological Diseases

NCT04698421 | Recruiting

• 1 other identifier: RC31/20/0150
• Study Type: observational
• Target: 1,000
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this project is to improve biological collections of patients presenting rare neurological disorders with known or suspected autoimmune origin. This collection will provide appropriate biological samples to identify new biomarkers and to be accessible to the medical, scientific and industrial communities for the identification of new therapeutic strategies.

Conditions

Nervous System Diseases

Keywords

autoimmune encephalitis; paraneoplastic neurological syndrome; myasthenia; paraneoplastic cerebellar degeneration; rare neuropathologies with known/suspected autoimmune origin

Outcome Measures

Primary Outcomes (1)

• Building a collection of biological samples and clinical-biological data from patients with rare autoimmune neurological diseases

  Blood sampling

  Day 0 and through study completion, an average of 1 year

Secondary Outcomes (3)

• Identification of new autoantibodies.

  Day 0 and through study completion, an average of 1 year

• Identification of biomarkers regarding the severity (such as cytokines, axonal damages...) in order to help the therapeutic decisions.

  Day 0 and through study completion, an average of 1 year

• Exploration of the pathophysiological mechanisms of rare autoimmune neurological pathologies.

  Day 0 and through study completion, an average of 1 year

Study Arms (1)

patients with rare autoimmune neurological diseases

Biological: Blood collection on admission and longitudinally

Interventions

Blood collection on admission and longitudinally BIOLOGICAL

Biological samples will be collected in the normal diagnosis and follow-up process. Only blood will be taken in larger quantity (8 tubes of 7mL).

patients with rare autoimmune neurological diseases

Eligibility Criteria

• Age: 6 Years - 99 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

patients followed at the Toulouse University Hospital and presenting rare neurological disorders with known or suspected autoimmune origin

You may qualify if:

• all patients with neurological disorders, with known or probable autoimmune involvement. This includes adults and children and peripheral and/or central nervous system symptoms.
• Social coverage up to date.

You may not qualify if:

• Patients with neurological damage from which the autoimmune character can be excluded.
• Known anemia and hemoglobin \<10 g / dl
• Patients under protective supervision (guardianship, curators)
• Pregnant or breastfeeding woman

Sponsors & Collaborators

• University Hospital, Toulouse: lead

Study Sites (1)

Purpan University Hospital

Toulouse, 31059, France

RECRUITING

MeSH Terms

Conditions

Nervous System Diseases; Autoimmune Diseases of the Nervous System; Paraneoplastic Cerebellar Degeneration

Condition Hierarchy (Ancestors)

Autoimmune Diseases; Immune System Diseases; Paraneoplastic Syndromes, Nervous System; Nervous System Neoplasms; Neoplasms by Site; Neoplasms; Paraneoplastic Syndromes; Cerebellar Diseases; Brain Diseases; Central Nervous System Diseases; Neurodegenerative Diseases

Study Officials

• Chloé Bost, PharmD, PhD

  University Hospital, Toulouse

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Chloé Bost, PharmD, PhD

CONTACT

5 61 77 61 44; bost.c@chu-toulouse.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 23, 2020
• First Posted: January 6, 2021
• Study Start: October 12, 2020
• Primary Completion (Estimated): January 1, 2030
• Study Completion (Estimated): September 3, 2030
• Last Updated: March 19, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)